Levels of Cholesterol in Small LDL Particles Predict Atherosclerosis Progression and Incident CHD in the HDL-Atherosclerosis Treatment Study (HATS)

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Williams, Paul T ^a   Zhao, Xue Qiao ^b   Marcovina, Santica M ^c   Brown, B Greg ^b   Krauss, Ronald M ^d  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN IIIB CHOLESTEROL; LOW DENSITY LIPOPROTEIN IVA CHOLESTEROL; NICOTINIC ACID; PLACEBO; SELENIUM; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DEATH; FEMALE; GEL ELECTROPHORESIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; CORONARY STENOSIS; DISEASE PROGRESSION; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; REGRESSION ANALYSIS;

EID: 84874548159     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056782     Document Type: Article

References (19)

1. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, et al. (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583-1592.
2. Krauss RM, Burke DJ, (1982) Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23: 97-104.
3. Berneis KK, Krauss RM, (2002) Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 43: 1363-1379.
4. Krauss RM, (2010) Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol 4: 305-311.
5. Rainwater DL, Mitchell BD, Comuzzie AG, Haffner SM, (1999) Relationship of low-density lipoprotein particle size and measures of adiposity. Int J Obes Relat Metab Disord 23: 180-189.
6. Kulkarni KR, (2006) Cholesterol profile measurement by vertical auto profile method. Clin Lab Med. 26: 787-802.
7. Williams PT, Superko HR, Haskell WL, Alderman EL, Blanche PJ, et al. (2003) Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003 23: 314-321.
8. Zhao XQ, Kosinski AS, Barnhart HX, Superko HR, King SB, (2003) Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty versus Surgery Trial. Med Sci Monit. 9: CR48-54.
9. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, et al. (2010) From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 466: 714-719.
10. Strong A, Ding Q, Edmondson AC, Millar JS, Sachs KV, et al. (2012) Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest. 122: 2807-2816.
11. Luc G, Fievet C, Arveiler D, Evans AE, Bard JM, et al. (1996) Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde. J Lipid Res 37: 508-517.
12. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, et al. (2000) VLDL, apolipoproteins B, CIII and E and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102: 1886-1892.
13. Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM, (2011) Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 124: 2065-2072.
14. Shin MJ, Krauss RM, (2010) Apolipoprotein CIII bound to apoB-containing lipoproteins is associated with small, dense LDL independent of plasma triglyceride levels in healthy men. Atherosclerosis 211: 337-341.
15. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, et al. (2006) Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 113: 691-700.
16. Hiukka A, Ståhlman M, Pettersson C, Levin M, Adiels M, et al. (2009) ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 58: 2018-2026.
17. Kawakami A, Yoshida M, (2009) Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb 16: 6-11.
18. Friedewald WT, Levy RI, Fredrickson DS, (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
19. AIM-HIGH Investigators (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med 365: 2255-2267.